Problem pathogens (Pseudomonas aerugìnosa and Acìnetobacter)

Seminars in Respiratory Infections

Volumn 15, Issue 4, 2000, Pages 287-298

  Chastre, Jean ^a   Trouillet, Jean Louis ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN; TICARCILLIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL TRIAL; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0034493651     PISSN: 08820546     EISSN: None     Source Type: Journal    
DOI: 10.1053/srin.2000.20944     Document Type: Article

References (56)

1. Nosocomial pneumonia in mechanically ventilated adult patients: Epidemiology and prevention in 1996
2. Epidemiology and risk factors for nosocomial pneumonia. Emphasis on prevention
3. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995
4. The increasing significance of outbreaks of Acinetobacter spp.: The need for control and new agents
5. Epidemiology of infections due to Pseudomonas aeruginosa
6. Nosocomial colonization and infection with multiresistant Acinetobacter baumannii: Outbreak delineation using DNA macrorestriction analysis and PCR-fingerprinting
7. Nosocomial Acinetobacter baumannii infections: Microbiological and clinical epidemiology
8. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam
9. National Nosocomial Infections Surveillance System: NNIS report data summary from January 1990-May 1999 issued June 1999
10. Invasive diagnostic testing should he routinely used to manage ventilated patients with suspected pneumonia
11. Invasive diagnostic testing is not needed routinely to manage suspected ventilator-associated pneumonia
12. Procedures for the diagnosis of pneumonia in ICU patients
13. Protected specimen brush or bronchoalveolar lavage to diagnose bacterial nosocomial pneumonia in ventilated adults: A meta-analysis
14. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay
15. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques
16. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients
17. Variations in etiology of ventilator-associated pneumonia across four treatment sites: Implications for antimicrobial prescribing practices
18. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria
19. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients
20. Nosocomial respiratory tract colonization and infection with aminoglycoside-resistant Acinetobacter calcoaceticus var anitratus: Epidemiologic characteristics and clinical significance
21. Nosocomial acquisition of multiresistant Acinetobacter baumannii: Risk factors and prognosis
22. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia
23. Risk factors for pneumonia, and colonization of respiratory tract and stomach in mechanically ventilated ICU patients
24. Risks and routes for ventilator-associated pneumonia with Pseudomonas aeruginosa
25. Gastroduodenal dysfunction and bacterial colonisation of the ventilated lung
26. Gastric colonization by gram-negative bacilli and nosocomial pneumonia in the intensive care unit patient. Evidence for causation
27. Outbreak of Pseudomonas aeruginosa infections in a surgical intensive care unit: Probable transmission via hands of a health care worker
28. Contaminated medication nebulizers in mechanical ventilator circuits. Source of bacterial aerosols
29. Control of colonization and transmission of pathogenic bacteria in the hospital
30. Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units. Implications for infection control
31. Nosocomial respiratory tract infection and colonization with Acinetobacter calcoaceticus. Epidemiologic characteristics
32. Endemic Acinetobacter anitratus in a surgical intensive care unit: Mechanical ventilators as reservoir
33. Multiple intensive care unit outbreak of Acinetobacter calcoaceticus subspecies anitratus respiratory infection and colonization associated with contaminated, reusable ventilator circuits and resuscitation bags
34. Plasmid DNA fingerprinting of Acinetobacter calcoaceticus subspecies anitratus from intubated and mechanically ventilated patients
35. Hospital infection with Acinetobacter spp.: An increasing problem
36. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee
37. Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients
38. The radiologic diagnosis of autopsy-proven ventilator-associated pneumonia
39. Detection of nosocomial lung infection in ventilated patients. Use of a protected specimen brush and quantitative culture techniques in 147 patients
40. Endotracheally administered antibiotics for gram-negative bronchopneumonia
41. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group
42. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals
43. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French Portuguese ICU Study Groups
44. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia
45. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: A prospective, observational study
46. Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units
47. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
48. Prospective, randomised, multicentre study of meropenem versus imipenem/ cilastatin as empiric monotherapy in severe nosocomial infections
49. Meropenem monotherapy as empiric treatment of nosocomial lower respiratory tract infection
50. Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: Prospective trial using the Zelen protocol
51. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients
52. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group
53. Pulmonary disposition of antimicrobial agents: In vivo observations and clinical relevance
54. Once-daily dosing of aminoglycosides: Review and recommendations for clinical practice
55. Antimicrobial action and pharmacokinetics/pharmacodynamics: The use of AUIC to improve efficacy and avoid resistance
56. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients